From UCLA Thoracic Oncology Translational Research
Current and open clinical trials have been announced at UCLA Main Campus and various satellite centers. The trials include:
Clinical Trial: Relapsed or Refractory Small Cell Lung Cancer
Dr. Jonathan Goldman’s TRIO L-07 now has open spots for patients. This is a Phase 2 study of continuous talazoparib plus intermittent low-dose temozolomide in patients with relapsed or refractory extensive-stage small cell lung cancer. Patients must have cytologically or histologically conformed small cell lung cancer and must be in relapsed (progressed within 6 months) or refractory (progressed during or within 4 weeks of completing 1st line platinum based regimen) stage of SCLC. This study is now open for enrollment in UCLA Main Campus.
Clinical Trial: Neoantigen Peptide Vaccine for NSCLC
Dr. Edward Garon’s Neon NT-002 study is now open to enrollment. This is a phase 1B study of the neoantigen peptide vaccine NEO-PV- 01 in combination with pembrolizumab plus carboplatin/pemetrexed chemotherapy in patients with advanced or metastatic (cancer that spreads) non-squamous NSCLC. The NEO-PV-01 vaccine is specific to each patient, and is designed based on sequence analysis of each patient’s tumor. In order to enroll, patients must not have received prior systemic treatment for their cancer and must not have EGFR and ALK mutations. This study is now open at UCLA Main Campus.
Clinical Trial: Phase 3 Neoadjuvent Study for Early Stage NSCLC
Dr. John Glaspy’s BMS CA209-816 study is now open at the following TRIO sites: Ft. Wayne, Holly- wood, Orlando, and Wichita. This is a randomized, open-label, phase 3 trial of nivolumab plus ipilimumab or nivolumab plus platinum-doublet chemotherapy versus platinum-doublet chemotherapy in early stage NSCLC. To be eligible, patients must have early stage NSCLC confirmed by histology. Patients must also have an Eastern Cooperative Oncology Group (ECOG) score of 0-1.